Skip to main content

Table 3 Characteristics and data of low-risk patients in the initial treatment (IVIG)-responsive and initial treatment-resistant groups

From: Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study

  IVIG-responder group IVIG-resistant group p value
number 116 28  
Age in month 29.5 [4–130] 22 [4–107] 0.352
Male gender, n (%) 56 (48.3) 13 (46.4) 0.861
Illness day at diagnosis 5 [2–10] 5 [3–8] 0.436
Kobayashi score 2 [0–4] 3 [0–4] 0.030
< Laboratory data before IVIG >
TN-C, ng/mL 106.6 [29.1–449.6] 113.5 [46.6–483.4] 0.432
WBC, × 103/μL 13.0 [6.1–32.3] 12.7 [6.3–22.0] 0.435
Neutrophil, % 66 [24–91] 67 [26–88] 0.418
Platelet, ×104/mL 33.3 [16.6–53.3] 32.9 [19.4–62.5] 0.612
CRP, mg/dL 6.7 [1.3–31.4] 8.8 [1.5–20.0] 0.190
Albumin, g/dL 3.6 [2.6–4.8]
n = 115
3.6 [2.6–4.3] 0.998
T-bilirubin, mg/dL 0.5 [0.1–3.1]
n = 114
0.6 [0.2–3.4] 0.064
AST, IU/L 34 [15–298] 33 [18–236] 0.677
ALT, IU/L 19 [5–442] 24 [8–237] 0.608
Sodium, mEq/L 136 [127–143] 135 [127–138] 0.093
  1. TN-C tenascin-C, WBC white blood cell, CRP C-reactive protein, AST aspartate aminotransferase, ALT alanine aminotransferase
  2. * The Kobayashi score [8] was < 5 points in all cases
  3. * In all cases, the first-line therapy was IVIG and aspirin